Cytori Therapeutics Reports Benefit of Adipose Stem and Regenerative Cells in Reconstructive Surgery from Preclinical Study
Very interesting...bwdik?
biz.yahoo.com
Best of Luck,
SS
<emphasis mine>
>>>>>>>>
Cytori Therapeutics Reports Benefit of Adipose Stem and Regenerative Cells in Reconstructive Surgery from Preclinical Study
Monday April 24, 9:30 am ET
SAN DIEGO--(BUSINESS WIRE)--April 24, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News) announced today that adipose stem and regenerative cells, when administered in combination with a fat graft, improved survival of the transplanted tissue in a preclinical study. The study results were presented by Cytori scientist Min Zhu, M.D., at the 2006 American Society for Aesthetic Plastic Surgery (ASAPS) Meeting in Orlando, Florida.
ADVERTISEMENT
"This study suggests that adipose stem and regenerative cells improve the long-term viability of soft tissue transfer, which holds promising implications for breast reconstruction, cosmetic surgery and repair of congenital defects," explained Marc H. Hedrick, M.D., President of Cytori Therapeutics. "Fat transplantations without a stem cell supplement often lead to partial survival of the transplanted tissue. Our findings show that the vascularization imparted by a stem cell supplement is likely a major contributor to increased tissue survival and volume retention. We look forward to evaluating this approach clinically in reconstructive surgery in the safety and feasibility study that was recently initiated using Cytori's Celution(TM) System."
In the reported preclinical study, fat tissue transfers were performed in 30 animals, which were divided into three groups of ten that were evaluated at one, three and six months. A supplement of adipose stem and regenerative cells were injected into the grafts of half of the animals in each group. After one and three months, no differences in weight or morphology were observed. After six months, a statistically significant, three-times greater weight retention was observed in the grafts injected with adipose stem and regenerative cells compared to the grafts from the control group.
About Cytori Therapeutics
Cytori Therapeutics, Inc., (NASDAQ:CYTX - News; Frankfurt:XMPA - News) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and prospects of our business which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses and expected continuing losses, the need for further financing, our ability to develop and commercialize regenerative cell-based therapies, our dependence on third parties, our ability to obtain, defend and enforce our intellectual property, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2005 and subsequent SEC filings, which will be available through our web site. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Contact:
Cytori Therapeutics, Inc.
Tom Baker, 858-875-5258 (Investors)
tbaker@cytoritx.com
or
Porter Novelli Life Sciences
Amy Beltran, Ph.D., 858-527-3489 (Media)
abeltran@pnlifesciences.com
--------------------------------------------------------------------------------
Source: Cytori Therapeutics, Inc. |
